Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

bioAffinity Technologies (BIAF) Gains from Investment Securities (2022 - 2025)

Historic Gains from Investment Securities for bioAffinity Technologies (BIAF) over the last 4 years, with Q3 2025 value amounting to $58031.0.

  • bioAffinity Technologies' Gains from Investment Securities fell 3625.63% to $58031.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $342310.0, marking a year-over-year decrease of 68.79%. This contributed to the annual value of $361181.0 for FY2024, which is 28737.53% up from last year.
  • bioAffinity Technologies' Gains from Investment Securities amounted to $58031.0 in Q3 2025, which was down 3625.63% from $92975.0 recorded in Q2 2025.
  • In the past 5 years, bioAffinity Technologies' Gains from Investment Securities registered a high of $2.0 million during Q2 2023, and its lowest value of $2159.0 during Q1 2022.
  • Over the past 4 years, bioAffinity Technologies' median Gains from Investment Securities value was $89552.5 (recorded in 2024), while the average stood at $273580.4.
  • In the last 5 years, bioAffinity Technologies' Gains from Investment Securities skyrocketed by 5084951.37% in 2023 and then plummeted by 9547.8% in 2024.
  • Over the past 4 years, bioAffinity Technologies' Gains from Investment Securities (Quarter) stood at $26692.0 in 2022, then soared by 179.25% to $74538.0 in 2023, then rose by 22.14% to $91038.0 in 2024, then plummeted by 36.26% to $58031.0 in 2025.
  • Its last three reported values are $58031.0 in Q3 2025, $92975.0 for Q2 2025, and $100266.0 during Q1 2025.